Plus Therapeutics Announces Positive Interim Data from ReSPECT-GBM Phase 1 Clinical Trial at the 2021 Society for Neuro-Oncology Annual Meeting (GlobeNewswire) - Nov 18, 2021 - P1/2, N=55; ReSPECT (NCT01906385); Sponsor: Plus Therapeutics; "No delivery failures were observed and an average absorbed dose of 267.5 Gy (range 8.9-740Gy) of radiation was delivered to the tumor; No dose limiting toxicities or adverse events (AEs) with the outcome of death, or discontinuations due to AEs have been observed; Of 22 total subjects with recurrent GBM treated with 186RNL, seven patients remain alive and mean and median overall survival (OS) is currently 336.6 days and 231.5 days, respectively....'We look forward to completing key drug scale-up activities and proceed to FDA discussions regarding CMC and next clinical steps in early 2022.'"
Clinical • P1/2 data • CNS Tumor • Glioblastoma • Glioma • Oncology
|